+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review

Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review

Clinical and Experimental Rheumatology 29(2 Suppl 65): S66-S74

Interstitial lung disease (ILD) in systemic sclerosis (scleroderma) is a rare and potentially lethal and devastating autoimmune disease, and yet the cause of it remains poorly understood. It is associated with tissue fibrosis not only in the lungs, but also other organs like the heart and kidneys. Although ILD can manifest itself in various disease presentations, ILD in systemic sclerosis is particularly and especially worrying because it has the highest case-specific mortality among all autoimmune rheumatic conditions. The unsatisfactory clinical outcome and prognosis for ILD in systemic sclerosis has, unsurprisingly, fuelled an intense search for early and accurate diagnosis, as well as new therapeutic strategies. Recent advances in diagnostic techniques and treatment interventions represent a significant step forward in our understanding and management of ILD in systemic sclerosis. Here, we review the current knowledge pertaining to the treatment of ILD in systemic sclerosis, and also address the various challenges involved as well as implications for the future.

(PDF emailed within 1 workday: $29.90)

Accession: 055398908

Download citation: RISBibTeXText

PMID: 21586221

Related references

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Research & Therapy 17(): 372-372, 2016

Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Current Rheumatology Reports 16(4): 411-411, 2014

FRI0274Predictors of Survival in Patients with Systemic Sclerosis-Related Interstitial Lung Disease Enrolled in The Scleroderma Lung Study II. Annals of the Rheumatic Diseases 75(Suppl 2): 534.2-534, 2016

Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 130(4): 976-981, 2006

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis & Rheumatology 69(7): 1451-1460, 2017

Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatology International: -, 2018

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. Journal of Rheumatology 20(5): 838-844, 1993

Interstitial Lung Disease (ILD) As A Sole Manifestation Of Visceral Involvement In Systemic Sclerosis Sine Scleroderma (ssSSc). Chest Journal 126(4): 993sa-1-993sa-2, 2004

Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Annals of the American Thoracic Society 13(11): 2045-2056, 2016

Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Inflammation & Allergy Drug Targets 11(4): 266-277, 2013

Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy. Inflammation & Allergy - Drug Targets 11(4): 266-277, 2012

Recent progress in systemic sclerosis-interstitial lung disease. Current Opinion in Rheumatology: -, 2018

Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine 9(Suppl 1): 97-110, 2016

Interstitial lung diseases : Advances in diagnosis and treatment.Disease state of idiopathic interstitial pneumonia and complication of lung cancer. Nihon Naika Gakkai Zasshi 83(5): 739-744, 1994

Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clinical and Experimental Rheumatology 34 Suppl 100(5): 170-176, 2016